Condition: Stereotactic Radiotherapy · Immunotherapy · Breast Cancer · Sponsor: Shengjing Hospital
This study was an open-label, multicenter, randomized study. It is planned to include 136 patients with stage II-III triple negative breast cancer. Eligible subjects will be randomized to receive either the experimental arm: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) or the control arm: adebrelimab plus nab-paclitaxel + carboplatin.
This description comes directly from the study's public registry record.
Caigang Liu, Dr. · 18940254967 · liucg@sj-hospital.org
Nan Niu, Dr. · 18940256668 · niunannancy@163.com
Always discuss trial participation with your own doctor first.
| Shengjing Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06165900